1. Home
  2. ANAB vs NRIX Comparison

ANAB vs NRIX Comparison

Compare ANAB & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • NRIX
  • Stock Information
  • Founded
  • ANAB 2005
  • NRIX 2009
  • Country
  • ANAB United States
  • NRIX United States
  • Employees
  • ANAB N/A
  • NRIX N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANAB Health Care
  • NRIX Health Care
  • Exchange
  • ANAB Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • ANAB 659.6M
  • NRIX 728.6M
  • IPO Year
  • ANAB 2017
  • NRIX 2020
  • Fundamental
  • Price
  • ANAB $31.83
  • NRIX $9.98
  • Analyst Decision
  • ANAB Buy
  • NRIX Strong Buy
  • Analyst Count
  • ANAB 10
  • NRIX 14
  • Target Price
  • ANAB $50.63
  • NRIX $29.07
  • AVG Volume (30 Days)
  • ANAB 749.6K
  • NRIX 1.2M
  • Earning Date
  • ANAB 11-04-2025
  • NRIX 10-09-2025
  • Dividend Yield
  • ANAB N/A
  • NRIX N/A
  • EPS Growth
  • ANAB N/A
  • NRIX N/A
  • EPS
  • ANAB N/A
  • NRIX N/A
  • Revenue
  • ANAB $123,164,000.00
  • NRIX $88,381,000.00
  • Revenue This Year
  • ANAB $11.40
  • NRIX $74.59
  • Revenue Next Year
  • ANAB $8.17
  • NRIX N/A
  • P/E Ratio
  • ANAB N/A
  • NRIX N/A
  • Revenue Growth
  • ANAB 304.17
  • NRIX 41.86
  • 52 Week Low
  • ANAB $12.21
  • NRIX $8.18
  • 52 Week High
  • ANAB $36.54
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 71.43
  • NRIX 59.24
  • Support Level
  • ANAB $29.49
  • NRIX $8.20
  • Resistance Level
  • ANAB $32.24
  • NRIX $10.23
  • Average True Range (ATR)
  • ANAB 2.08
  • NRIX 0.47
  • MACD
  • ANAB 0.81
  • NRIX 0.23
  • Stochastic Oscillator
  • ANAB 82.04
  • NRIX 95.42

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: